Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an Immunoglobulin presented as an intravenous solution for intravenous use. It provides passive immunity and is used to treat primary and secondary immunodeficiency diseases, immune thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Iqymune is an intravenous immunoglobulin used to replace deficient antibodies in various immune‑related conditions. - Primary immunodeficiency diseases: supplies pooled IgG to reduce infection frequency. - Secondary immunodeficiency: restores antibody levels in patients with acquired immune deficits. - Immune thrombocytopenic purpura (ITP): modulates immune response to increase platelet counts. - Kawasaki disease: reduces inflammation and coronary artery complications. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves nerve function by immune modulation.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typical infusion‑related reaction. - Nausea or fatigue: generally resolves after infusion.

Serious or Rare Side Effects: - Aseptic meningitis: presents with severe headache and neck stiffness. - Thromboembolic events: risk of clot formation, especially in high‑risk patients. - Renal failure: acute kidney injury may occur, monitor renal function. - Anaphylaxis or severe allergic reaction: requires immediate medical attention. - Hemolysis: destruction of red blood cells, leading to anemia.

Before initiating therapy, evaluate patient history and monitor relevant clinical parameters. - Assess renal function: check creatinine and adjust infusion rate if impaired. - Monitor for thrombotic risk: consider prophylaxis in patients with known risk factors. - Screen for IgA deficiency: patients may develop severe reactions. - Observe during infusion: watch for signs of anaphylaxis or hemolysis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intravenous immunoglobulin can interact with several medications, requiring careful management. Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immune modulation. - Immunosuppressants (e.g., rituximab): may reduce efficacy of IVIG. - Thrombolytic agents: increased risk of thrombosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for additive hypotensive effects. - Diuretics: watch fluid balance and renal function during therapy.